交易中 09-20 15:32:52 美东时间
+0.005
+20.00%
Lixte Biotechnology Provides Update on Recent Activities and Developments
08-19 20:30
Lixte Biotechnology: Got Into Clinical Trial Agreement With Netherlands Cancer ...
06-14 20:37
Lixte Biotechnology: Agreement to Conduct a Phase 1B/2 Clinical Trial of Lb-100...
06-14 20:37
An announcement from Lixte Biotechnology Holdings (LIXT) is now available. In a...
06-06 05:04
LIXTE Biotechnology Holdings(NASDAQ:LIXT) has announced the appointment of Jan Schellens, M.D., Ph.D., as CMO. He assumes the CMO role at LIXTE effective Aug. 1, 2024, succeeding James S. Miser, M.D.,...
06-03 22:21
Lixte Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Ch...
06-03 20:30
Recent Findings Relate to LIXTE's Lead Clinical Compound, LB-100, to be Present...
05-08 21:25
Shares of Lixte Biotechnology (NASDAQ:LIXT) were up nearly 60% in afternoon trading Wednesday after the company reported the publication of positive preclinical data for its lead clinical asset LB-100...
03-28 02:43
The company announced the publication of pre-clinical data in the online journal, "Cancer Discovery", showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled "Paradoxical activation of oncogenic signaling as a cancer treatment strategy."
03-27 22:56
https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11866444
01-09 18:36